Cyclosporine use in “dry eye” syndrome

Cover Page

Cite item

Full Text

Abstract

This literature review focuses on the need for anti-inflammatory therapy for “dry eye” disease (DED). Causes of development and mechanisms of pathogenesis of DED are presented. Principles of action of various groups of anti-inflammatory medications, as well as recommendations for cyclosporine use of are described. The results of studies on cyclosporine efficacy are highlighted, principles of cyclosporin prescription in DED are listed.

About the authors

Inna A. Riks

Pavlov First Saint Petersburg State Medical University

Author for correspondence.
Email: riks0503@yandex.ru
SPIN-code: 4297-6543

MD, PhD, Assistant Professor, Ophthalmology Department

Russian Federation, 6/8, Lva Tolstogo street, St. Petersburg, 197089

References

  1. Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802-812. https://doi.org/10.1016/j.jtos.2017.08.003.
  2. DEWS Epidemiology. The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):93-107. https://doi.org/10.1016/S1542-0124(12)70082-4.
  3. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the shihpai eye study. Ophthalmology. 2003;110(6):1096-1101. https://doi.org/10.1016/S0161-6420(03)00262-8.
  4. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105(6):1114-9. https://doi.org/10.1016/S0161-6420(98)96016-X.
  5. DEWS Epidemiology. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):75-92. https://doi.org/10.1016/s1542-0124(12)70081-2.
  6. Davis EA, Dohlman CH. Neurotrophic keratitis. Int Ophthalmol Clin. 2001;41(1):1-11. https://doi.org/10.1097/00004397-200101000-00003.
  7. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989-995. https://doi.org/10.1038/sj.eye.6700616.
  8. Benítez del Castillo JM, Wasfy MA, Fernandez C, Garcia-Sanchez J. An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye. Invest Ophthalmol Vis Sci. 2004;45(9):3030-3035. https://doi.org/10.1167/iovs.04-0251.
  9. Creuzot-Garcher C. La sécheresse oculaire liée aux médications systémiques. J Fr Ophtalmol. 2009;32(1):64-70. https://doi.org/10.1016/j.jfo.2008.11.001.
  10. Apostol S, Filip M, Dragne C, Filip A. Dry eye syndrome. Etiological and therapeutic aspects. Oftalmologia. 2003;59(4):28-31.
  11. Kam WR, Sullivan DA. Neurotransmitter influence on human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci. 2011;52(12):8543-8548. https://doi.org/10.1167/iovs.11-8113.
  12. Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1 % cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287-296. https://doi.org/10.5301/ejo.5000779.
  13. Goto E, Tseng SC. Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images. Arch Ophthalmol. 2003;121(2):173-180. https://doi.org/10.1001/archopht.121.2.173.
  14. Сафонова Т.Н., Овчинникова А.А., Федоров А.А., Полунин Г.С. Сухой кератоконъюнктивит при синдроме Шегрена: диагностическое значение изменения относительного белкового состава слезы // Вестник офтальмологии. – 1998. – Т. 114. – № 2. – C. 40–42. [Safonova TN, Ovchinnikova AA, Fedorov AA, Polunin GS. Suhoy keratokonyunktivit pri sindrome Shegrena: diagnosticheskoe znachenie izmeneniya otnositel’nogo belkovogo sostava slezy. Annals of ophthalmology. 1998;114(2):40-42. (In Russ.)]
  15. Бржеский В.В., Попов В.Ю., Калинина И.В., и др. Эффективность 0,01 % раствора дексаметазона в комплексной терапии больных с синдромом «сухого глаза» // Офтальмологические ведомости. – 2016. – Т. 9. – № 3. – С. 32–44. [Brzheskiy VV, Popov VYu, Kalinina IV, et al. Efficacy of 0.01 % dexamethasone solution in comprehensive therapy of dry eye disease. Oftalmologicheskie vedomosti. 2016;9(3):32-44. (In Russ.)]. https://doi.org/10.17816/OV9332-44.
  16. Бржеский В.В., Егорова Г.Б., Егоров Е.А. Синдром «сухого глаза» и заболевания глазной поверхности: клиника, диагностика, лечение. – М.: ГЭОТАР-Медиа, 2016. – 464 с. [Brzheskiy VV, Egorova GB, Egorov EA. The dry eye disease and ocular surface disease: clinical features, diagnosis, treatment. Moscow: GEOTAR-Media; 2016. 464 р. (In Russ.)]
  17. Патент РФ на изобретение RU № 2559580. Бржеский В.В., Садовникова Н.Н., Прозорная Л.П., Попов В.Ю. Препарат для лечения синдрома «сухого глаза». [Patent RUS No. 2559580. Brzheskiy VV, Sadovnikova NN, Prozornay LP, Popov VYu. The medicine for treatment of dry eye disease. (In Russ.)]. Доступно по: https://findpatent.ru/patent/255/2559580.html. Ссылка активна на 13.07.2019.
  18. Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55(1):203-208. https://doi.org/10.3349/ymj.2014.55.1.203.
  19. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526-535. https://doi.org/10.1016/j.exer.2006.02.004.
  20. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811-816. https://doi.org/10.1016/S0161-6420(99)90171-9.
  21. Knop E, Knop N. The role of eye-associated lymphoid tissue in corneal immune protection. J Anat. 2005;206(3):271-285. https://doi.org/10.1111/j.1469-7580.2005.00394.x.
  22. Knop N, Knop E. Conjunctiva-associated lymphoid tissue in the human eye. Am J Ophthalmol. 2000;130(3):385. https://doi.org/10.1016/s0002-9394(00)00700-5.
  23. Калинина Н.М., Попов В.Ю., Бржеский В.В. Роль цитокинов слёзной жидкости в развитии синдрома «сухого глаза» // Цитокины и воспаление. – 2015. – Т. 14. – № 1. – С. 5–10. [Kalinina NM, Popov VY, Brzheskiy VV. The role of lacrimal fluid cytokines in the development of dry eye disease (review). Cytokines & inflammation. 2015;14(1):5-10. (In Russ.)]
  24. Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol. 1977;22(2):69-87. https://doi.org/10.1016/0039-6257(77)90087-x.
  25. Sonoda S, Uchino E, Nakao K, Sakamoto T. Inflammatory cytokine of basal and reflex tears analysed by multicytokine assay. Br J Ophthalmol. 2006;90(1):120-122. https://doi.org/10.1136/bjo.2005.076737.
  26. Янченко С.В. Оптимизация диагностики и терапии возрастной формы синдрома «сухого глаза»: Автореф. дис. … д-ра мед. наук. – СПб., 2010. – 39 с. [Yanchenko SV. Optimizatsiya diagnostiki i terapii vozrastnoy formy sindroma «sukhogo glaza». [dissertation] Saint Petersburg; 2010. 39 р. (In Russ.)]. Доступно по: https://search.rsl.ru/ru/record/01004612320. Ссылка активна на 14.07.2019.
  27. Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1 % cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678-685. https://doi.org/10.5301/ejo.5001002.
  28. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342. https://doi.org/10.1016/j.ajo.2003.10.036.
  29. Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192-198.
  30. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1 % ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112(10):1790-1794. https://doi.org/10.1016/j.ophtha.2005.05.013.
  31. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1 % ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12(4):315-323. https://doi.org/10.1097/00003226-199307000-00007.
  32. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin a phase 2 study group. Ophthalmology. 2000;107(5):967-974. https://doi.org/10.1016/s0161-6420(00)00035-x.
  33. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-125. https://doi.org/10.1016/ s0162-3109(00)00192-2.
  34. Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204. https://doi.org/10.1155/ 2012/604204.
  35. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531-541. https://doi.org/10.1111/jphp.12075.
  36. Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits. Cornea. 2013;32(3): 345-54. https://doi.org/10.1097/ICO.0b013e31825e83f4.
  37. Tavares Fde P, Fernandes RS, Bernardes TF, et al. Dry eye disease. Semin Ophthalmol. 2010;25(3):84-93. https://doi.org/10.3109/08820538.2010.488568.
  38. Fujishima H, Fuseya M, Ogata M, Murat D. Efficacy of bromfenac sodium ophthalmic solution for treatment of dry eye disease. Asia Pac J Ophthalmol (Phila). 2015;4(1):9-13. https://doi.org/10.1097/APO.0000000000000032.
  39. Guidera AC, Luchs JI, Udell IJ. Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001;108(5):936-944. https://doi.org/10.1016/s0161-6420(00)00538-8.
  40. Lindstrom R. The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin. 2006;46(4):7-11. https://doi.org/10.1097/01.iio.0000212131.98760.a9.
  41. Hersh PS, Rice BA, Baer JC, et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990;108(4):577-583. https://doi.org/10.1001/archopht.1990.01070060125062.
  42. Moon I, Kang HG, Yeo A, et al. Comparison of ocular surface mucin expression after topical ophthalmic drug administration in dry eye-induced mouse model. J Ocul Pharmacol Ther. 2018;34(9): 612-620. https://doi.org/10.1089/jop.2018.0005.
  43. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci. 2001;42(3):653-659.
  44. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120(3):330-337. https://doi.org/10.1001/archopht.120.3.330.
  45. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27(1):64-69. https://doi.org/10.1097/ICO.0b013e318158f6dc.
  46. Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1 % (Voltaren ophtha), versus sodium chloride, 5 %, in the treatment of filamentary keratitis. Cornea. 2000;19(2):145-147. https://doi.org/10.1097/00003226-200003000-00005.
  47. Aragona P, Stilo A, Ferreri F, Mobrici M. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients. Eye (Lond). 2005;19(5):535-539. https://doi.org/10.1038/sj.eye.6701537.
  48. Li Y, Johnson N, Capano M, et al. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004;383(Pt 1):101-109. https://doi.org/10.1042/BJ20040669.
  49. Agarwal P, Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine A. Drug Discov Today. 2016;21(6):977-988. https://doi.org/10.1016/j.drudis.2016.04.002.
  50. Mandal A, Gote V, Pal D, et al. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa) for dry eye disease. Pharm Res. 2019;36(2):36. https://doi.org/10.1007/s11095-018-2556-5.
  51. Hoy SM. Ciclosporin ophthalmic emulsion 0.1 %: a review in severe dry eye disease. Drugs. 2017;77(17):1909-1916. https://doi.org/10.1007/s40265-017-0834-x.
  52. de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115-1122. https://doi.org/10.2147/OPTH.S184412.
  53. Luchs J. Phase 3 clinical results of cyclosporine 0.09 % in a new nanomicellar ophthalmic solution to treatment keratoconjunctivitis sicca. In: American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Washington, DC; 2018.
  54. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. Clin Ophthalmol. 2018;12:1921-1929. https://doi.org/10.2147/OPTH.S175065.
  55. Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046-50. https://doi.org/10.1001/archopht.126.8.1046.
  56. Chun YH, Beak JU, Kim HS, Na KS. Topical cyclosporine pretreatment of ocular surface in allogeneic hematopoietic stem cell transplant recipients. J Ocul Pharmacol Ther. 2018;34(9):628-632. https://doi.org/10.1089/jop.2018.0006.
  57. Dastjerdi MH, Hamrah P, Dana R. High-frequency topical cyclosporine 0.05 % in the treatment of severe dry eye refractory to twice-daily regimen. Cornea. 2009;28(10):1091-1096. https://doi.org/10.1097/ICO.0b013e3181a16472.
  58. Gire AI, Karakus S, Ingrodi SM, Akpek EK. Frequent dosing of topical cyclosporine a for severe ocular surface disease. J Ocul Pharmacol Ther. 2016;32(3):150-154. https://doi.org/10.1089/jop.2015.0078.
  59. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584-589. https://doi.org/10.1097/00003226-199811000-00002.
  60. Бржеский В.В., Сомов Е.Е. Роговично-конъюнктивальный ксероз (диагностика, клиника, лечение). – 2-е изд., частично перераб. и доп. – СПб.: Левша. Санкт-Петербург, 2003. – 120 с. [Brzheskiy VV, Somov E.E. Rogovichno-kon’’yunktival’niy kseroz (diagnostika, klinika, lechenie). 2nd ed, revised and updated. Saint Petersburg: Levsha. Saint Petersburg; 2003. 120 p. (In Russ.)]
  61. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444-457. https://doi.org/10.1016/j.ajo.2004.04.052.
  62. Труфанов С.В., Суббот А.М., Маложен С.А., Крахмалева Д.А. Гипотеза иммунной привилегии роговицы и патофизиология отторжения кератотрансплантата // Вестник офтальмологии. – 2016. – Т. 132. – № 5. – С. 117–124. [Trufanov SV, Subbot AM, Malozhen SA, Krakhmaleva DA. Hypothesis of immune privilege of the cornea and pathophysiology of graft rejection. Annals of ophthalmology. 2016;132(5):117-124. (In Russ.)]. https://doi.org/10.17116/oftalma20161325117-124.
  63. Труфанов С.В., Суббот А.М., Маложен С.А., и др. Факторы риска, клинические проявления, методы профилактики и лечения реакции отторжения трансплантата роговицы // Вестник офтальмологии. – 2016. – Т. 132. – № 6. – С. 108–116. [Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. Annals of ophthalmology. 2016;132(6):108-116. (In Russ.)]. https://doi.org/10.17116/oftalma20161326108-116.

Copyright (c) 2019 Riks I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies